Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy

被引：0
|
作者：
Tada, K. [1 ,2 ]
Shoji, H. [3 ]
Kitano, S. [4 ]
Nishimura, T. [5 ]
Shimada, Y. [3 ]
Nagashima, K. [6 ]
Ito, A. [7 ]
Honma, Y. [3 ]
Iwasa, S. [3 ]
Okita, N. [3 ]
Takashima, A. [3 ]
Kato, K. [3 ]
Yamada, Y. [3 ]
Katayama, N. [8 ]
Boku, N. [3 ]
Heike, Y. [1 ]
Hamaguchi, T. [3 ]
机构：
[1] St Lukes Int Hosp, Immunotherapy & Cell Therapy Serv, Tokyo, Japan
[2] Natl Canc Ctr, Div Canc Immunotherapy, Tokyo, Japan
[3] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[4] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[5] Tokyo Jikei Med Univ, Gastrointestinal Med Div, Tokyo, Japan
[6] Chiba Univ, Dept Global Clin Res, Chiba, Japan
[7] Natl Canc Ctr, Hematopoietci Stem Cell Transplant Div, Tokyo, Japan
[8] Mie Univ, Dept Hematol & Oncol, Tsu, Mie 514, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30240-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
406
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [41] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
    Karacetin, D.
    Yalcin, B.
    Okten, B.
    Ozturk, S.
    Maral, O.
    Incekara, O.
    JOURNAL OF BUON, 2009, 14 (04): : 605 - 608
  • [42] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Muscle volume loss after the induction of first-line chemotherapy as a novel prognostic factor in metastatic colorectal cancer patients
    Yoshikawa, Yusuke
    Okabayashi, Koji
    Hasegawa, Hirotoshi
    Tsuruta, Masashi
    Seishima, Ryo
    Takahashi, Hidena
    Yamada, Toru
    Matsui, Shimpei
    Kondo, Takayuki
    Shimada, Takehiro
    Matsuda, Mutsuhito
    Yahagi, Masashi
    Asada, Yusuke
    Sugiura, Kiyoaki
    Suzuki, Yoshiyuki
    Tajima, Yuki
    Nakadai, Junpei
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [44] Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy
    Mizushima, Tsunekazu
    Fukunaga, Mutsumi
    Sueda, Toshinori
    Ikeda, Masataka
    Kato, Takeshi
    Kim, Ho Min
    Kudo, Toshihiro
    Murata, Kohei
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Yamamoto, Hirofumi
    Doki, Yuichiro
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (01) : 81 - 90
  • [45] Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy
    Tsunekazu Mizushima
    Mutsumi Fukunaga
    Toshinori Sueda
    Masataka Ikeda
    Takeshi Kato
    Ho Min Kim
    Toshihiro Kudo
    Kohei Murata
    Junichi Nishimura
    Taishi Hata
    Chu Matsuda
    Hirofumi Yamamoto
    Yuichiro Doki
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 81 - 90
  • [46] Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study
    Inal, Ali
    Kaplan, M. Ali
    Kucukoner, Mehmet
    Urakci, Zuhat
    Guven, Mehmet
    Nas, Necip
    Yunce, Muharrem
    Isikdogan, Abdurrahman
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (08) : 3869 - 3872
  • [47] Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy
    Basile, D.
    Broudin, C.
    Emile, J-F.
    Falcoz, A.
    Toullec, C.
    Bennouna, J.
    Louvet, C.
    Desrame, J.
    Fratte, S.
    Andre, T.
    Taieb, J.
    Svrcek, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S533 - S533
  • [48] CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Yukiya Narita
    Hiroya Taniguchi
    Azusa Komori
    Sohei Nitta
    Kazuhisa Yamaguchi
    Chihiro Kondo
    Motoo Nomura
    Shigenori Kadowaki
    Daisuke Takahari
    Takashi Ura
    Masashi Andoh
    Kei Muro
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 409 - 416
  • [49] CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Narita, Yukiya
    Taniguchi, Hiroya
    Komori, Azusa
    Nitta, Sohei
    Yamaguchi, Kazuhisa
    Kondo, Chihiro
    Nomura, Motoo
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 409 - 416
  • [50] Place of first-line palliative chemotherapy in patients with metastatic colorectal cancer
    Hebbar, M
    REVUE DE MEDECINE INTERNE, 1997, 18 : S364 - S367
12345